Avalon Globocare shares surge 23.64% after hours on FDA registration renewal and Q2 2026 B2B/B2C launch via Catch-Up AI platform.

Avalon GloboCare Corp. surged 23.64% in after-hours trading following the announcement of FDA registration renewal for its KetoAir™ breathalyzer and a planned Q2 2026 B2B/B2C launch via its AI-powered Catch-Up™ SaaS platform. The FDA renewal validates the device’s regulatory compliance, enabling continued U.S. market operations, while the launch strategy leverages generative AI for scalable marketing, signaling expanded distribution and revenue potential. The company emphasized that these steps represent key milestones, with the Catch-Up™ initiative aiming to accelerate adoption across enterprise and consumer markets. The significant after-hours rally reflects investor optimism about the product’s market prospects and the company’s strategic pivot toward AI-driven commercialization.